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Background: Functional abdominal pain (FAP) is not only a highly prevalent disease but also poses a considerable
burden on children and their families. Untreated, FAP is highly persistent until adulthood, also leading to an
increased risk of psychiatric disorders. Intervention studies underscore the efficacy of cognitive behavioral treatment
approaches but are limited in terms of sample size, long-term follow-up data, controls and inclusion of psychosocial
outcome data.
Methods/Design: In a multicenter randomized controlled trial, 112 children aged 7 to 12 years who fulfill the Rome
III criteria for FAP will be allocated to an established cognitive behavioral training program for children with FAP
(n = 56) or to an active control group (focusing on age-appropriate information delivery; n = 56). Randomization
occurs centrally, blockwise and is stratified by center. This study is performed in five pediatric gastroenterology
outpatient departments. Observer-blind assessments of outcome variables take place four times: pre-, post-, 3- and
12-months post-treatment. Primary outcome is the course of pain intensity and frequency. Secondary endpoints
are health-related quality of life, pain-related coping and cognitions, as well as selfefficacy.
Discussion: This confirmatory randomized controlled clinical trial evaluates the efficacy of a cognitive behavioral
intervention for children with FAP. By applying an active control group, time and attention processes can be
controlled, and long-term follow-up data over the course of one year can be explored.
Trial registration: DRKS00005038 (date: 25 July 2013); NCT02030392 (date: 7 January 2014)
Keywords: FAP, Randomized controlled trial, Cognitive behavioral intervention, Children, PainBackground
Functional abdominal pain (FAP) is a chronic pain
disorder of the gastrointestinal tract without underlying
pathological condition [1]. According to the Rome III
criteria, functional abdominal pain is specified as func-
tional dyspepsia, irritable bowel syndrome, functional
abdominal pain, and functional abdominal pain syn-
drome [2]. FAP is characterized by recurrent or persist-
ent pain in the abdomen for more than 2 months, with
episodes occurring at least once a week [2]. FAP repre-
sents, besides headache, the most common pain syn-
drome in childhood [3], with prevalence rates ranging
from 8.3% [3] up to 45% [2]. FAP often leads to* Correspondence: warschb@uni-potsdam.de
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article, unless otherwise stated.functional disability [4], poor school attendance [4] and
a number of unnecessary, cost-intensive visits in med-
ical care settings [5]. Children with recurrent episodes
of abdominal pain may have a worse quality of life [6]
and self-esteem [4] and experience greater anxiety and
depression [7,8]. Untreated, FAP is highly persistent
until adulthood, also leading to increased risk of psychi-
atric disorders (see [9]).
Psychosocial factors in symptom maintenance include
inadequate coping styles [10], poor family functioning
and overprotective parental behaviors [11]. Catastrophiz-
ing plays an especially important role in mediating the
relationship between pain and quality of life [6] and
moderating the effectiveness of distraction [12].
Systematic reviews and meta-analyses underscore
the efficacy of psychological interventions, especially
cognitive-behavioral therapy (CBT), for managing painentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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treatment studies for pediatric chronic pain consider
abdominal pain (3 out of 25; see [16]) and even fewer
investigate the emotional functioning of the children
[16,18]. A recent meta-analysis by Sprenger et al. [18],
including ten studies for the psychological treatment
of FAP, showed that interventions obtain a medium-
sized effect on pain reduction. These interventions
mainly comprised CBT, child-centered or family-based,
and relaxation techniques. With respect to functional
and emotional outcomes, CBT involving the children
alone [19] or parents and children [11,20-22] proved to be
effective in terms of an increase in emotional functioning
or in quality of life. Interpretation of studies is limited due
to differing definitions of the condition, inadequate con-
trol group designs and a lack of assessment of long-term
effects [16]. With respect to longer term follow-up and
the effectiveness of CBT compared to an active control
group, available evidence is limited. Since preparation of
this trial, several RCT studies with 12-month follow-up
data have been published [23,24] but with inconsistent re-
sults. While Levy et al. [11,23] report a greater decrease in
pain symptoms and parental solicitous behavior, as well as
greater increase in child’s coping skills in the intervention
group compared to the active control group, results of
the study by van der Veek et al. [24] could not confirm
these differences. Comparing a cognitive-behavioral,
child-centered intervention and intensive medical care,
van der Veek et al. [24] found no group differences in
pain reduction at post-treatment and at the 12-month
follow-up. All secondary outcomes, for example, quality
of life, improved equally in both groups.
The current trial builds on the insights gained in two
previous studies. For example, in an uncontrolled pilot
study with 11 children, we were able to show that chil-
dren attending a cognitive-behavioral program [20] not
only experienced a reduction in pain frequency and in-
tensity, but also an increase in health-related quality of
life. A small RCT-study (n = 29; including a waiting list
control group) was able to confirm these results with
effect sizes ranging from medium to high for a 3-
month follow-up period [21,22].
Taken together, these data suggest that cognitive-
behavioral interventions are effective for pain reduction;
however little is known about the differential effects on
emotional well-being and individual differences in treat-
ment response.
This multicenter trial aims to compare the cognitive-
behavioral group intervention with an active control
group (age-appropriate educational content), both pro-
vided by trained therapists, with respect to a reduction
of pain symptoms and an increase in children’s quality
of life. The effects are analyzed 3 and 12 months after
the end of treatment.Methods/Design
Study design
Stop-FAP is a multicenter, prospective, parallel group,
randomized-controlled superiority trial for the evaluation
of the efficacy of a cognitive-behavioral group intervention
compared to an active control group. Study process from
enrollment to follow-up is depicted in Figure 1 (Trial Flow
Chart).
Study setting
This study is conducted in five study centers, all of which
are outpatient clinics for pediatric gastroenterology (Berlin,
Darmstadt, Düsseldorf, Hamburg, Ulm). Participating study
centers and investigators are fully listed in the German
Clinical Trials Register (DRKS00005038) and in the registry
of the U.S. National Institutes of Health clinicaltrials.gov
(NCT02030392).
Recruitment
After initiation of the study centers, the 12-month re-
cruitment phase of this ongoing trial started in March
2014. Patients will be recruited consecutively during
regular consulting hours. Supplementary recruitment
strategies involve active recruitment by information flyers
and posters or by informing former patients about the
study.
Participants
Study inclusion follows a stepwise procedure. In the first
step we defined eligibility criteria for medical screening
as listed below:
Medical screening
Inclusion criteria include the following:
1. age 7 to 12 years,
2. Rome III criteria for FAP (that is, abdominal
pain at least once per week for at least two
months), and
3. unexplained cause for abdominal pain.
Exclusion criteria include the following:
1. insufficient German language skills,
2. mental retardation,
3. physician-ordered medication or therapy
(psychological, pharmacological) of gastrointestinal
complaints at the screening visit,
4. participation in a clinical trial that may have effects
on gastrointestinal symptoms in the preceding
4 weeks,
5. participation in a training program for
gastrointestinal complaints in the preceding
6 months, or
Figure 1 Trial flow chart.
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from abdominal pain.
The standardized procedure of gastroenterological
diagnostics is explained in more detail in the section
‘procedures’ below. In the second step, we defined inclu-
sion criteria for study participation as follows:
1. functional abdominal pain (FAP) presenting as
functional dyspepsia, irritable bowel syndrome,
functional abdominal pain or functional abdominal
pain syndrome (Rome-III Criteria H2a, H2b, H2d,
H2d1), and
2. informed written consent of parent(s) and child.Exclusion criteria for study participation are as follows:
1. severe internalizing psychiatric disorders with
primary treatment indication, or
2. very limited group skills that are operationalized as
severe externalizing disorders.
Sites (n = 5) were selected based on the availability of a
pediatric gastroenterological consultation hours and staff
experienced in diagnosis and treatment for FAP (for
example, certified by the German Society for Pediatric
Gastroenterology and Nutrition, GPGE). Eligibility cri-
teria for the selection of trainers (n = 10) were expertise
and occupational background for pediatric psychology,
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children with chronic diseases. All trainers received an
intensive training in conducting both interventional and
control training (IG and CG) during a mandatory 3-day
train-the-trainer seminar.Procedures: identification of trial participants
Prior to study inclusion, children will undergo standard-
ized medical and psychological examination to exclude
organic gastrointestinal disorders in the first step and
psychiatric disorders with primary treatment indication
in the second step (see Figure 2). Information about pain
symptoms and associated factors (somatoform symp-
toms and family history of pain) is collected during theFigure 2 Procedures: identification of trial participants.screening process by parent questionnaire. We aim to
screen n = 450 children.Medical screening
Medical screening for exclusion of organic gastrointes-
tinal disorders is standardized across study centers and
follows current guidelines [1,25,26]. Following a stepwise
approach, the physician will clarify red flags by a stan-
dardized medical history (related symptoms, fever, blood
in the urine, waking up during night, bowel habits, nau-
sea etcetera), thorough examination and laboratory diag-
nostics (that is, blood, urine status, and stool), all of
which are obligatory and necessary steps to rule out or-
ganic causes of pain such as inflammatory bowel disease
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will be conducted accordingly (for example, elimination
diet in case of signs of food intolerance). According to
the Rome III criteria, in case of no pathological result, a
diagnosis of FAP can be established. At this point, infor-
mation about the trial will be given to the child and par-
ents, and written consent will be obtained by the site
investigator.
Psychological screening
In the next step, the child will be referred for psycho-
logical screening, to rule out primary severe psychological
problems associated with abdominal pain. The psycho-
logical diagnostics follow a two-step procedure, with a
standardized and validated screening questionnaire (SDQ;
[27-29]) for all parents of eligible children in the first step.
In case of subclinical or clinical scores on the scales for
emotional problems, hyperactivity or conduct problems, a
structured clinical interview (Kinder-DIPS; [30]) with the
parent will be held to verify the reported abnormalities
(see [31]), to determine psychological strain, group skills
and treatment indication.
Since up to 45% of the FAP children suffer from psycho-
logical problems - mainly in the subclinical range [7,8] -
we do include children with subclinical psychological
disorders to ensure that we are able to collect a representa-
tive study sample. Children with clinically relevant psychi-
atric symptoms will only be included when FAP is declared
to be associated with the highest psychological strain lead-
ing to primary treatment indication.
Intervention and controls
Intervention group (IG) and control group (CG) are
comparable with regard to group size (3 to 8 children),
number and duration of sessions for children (n = 6,
90 min each) and parents (n = 2, 50 min each). Training
sessions for children are once a week. In both groups,
the intervention period per patient lasts 6 weeks in the
study centers, with 2 weeks pre- and postintervention
being added for the pain diary. All study centers conduct
both treatment approaches.
Standardization
Both experimental and control intervention are manua-
lized programs for maximizing standardization and im-
proving protocol adherence.
Intervention group - stop the pain with happy pingu
Children and their parents randomized to the IG will
participate in the cognitive behavioral self-management
program ‘Stop the Pain with Happy Pingu’ [32]. The
standardized and manualized intervention addresses the
following issues: psychoeducation on FAP, change of nega-
tive pain-related thoughts and attention bias, relaxationtechniques, coping strategies and self-esteem. Each session
includes individual tailoring of content, for example, trig-
gers of pain. A central element of the program is the pain
diary that children are asked to keep during the whole
intervention in order to increase their self-management
skills. Each session is accompanied by regular homework
(for example, relaxation) that allows implementing and
practicing of the newly learned strategies at home. The
child’s experiences can be tackled in the following session.
During the parent group sessions, the parents are pri-
marily informed about the major disease characteristics,
the etiology and maintenance of FAP, red flags and
nutrition. Main focus of the parental sessions is to coach
the parents on how to support their child in his pain
management efforts.
Control group - educational program
The CG comprises a child-centered educational program
[33,34]. The sessions will include information mainly
about the gastrointestinal tract, nutrition and bodily
activity. Adverse side effects of this program are not re-
ported [20-22]. In order to measure the course of pain
severity continuously, the CG will fill in the pain diary
as weekly homework. For ethical reasons, we will inform
the parents about the so-called red flags that indicate
the need for contacting a medical doctor [1,25]. All par-
ents will be reassured that there is no serious organic
disease present and that the pain of their child is real.
There will be no recommendations by the therapist for
any food or diet and neither parent nor child will receive
a specific training to cope with pain.
Treatment integrity and protocol adherence
The quality of the intervention is assured by the standard-
ized manual and a mandatory 3-day train-the-trainer
seminar for all the persons conducting the intervention,
followed by ongoing supervision via regular telephone
calls (once a month) and conferences (every 3 months)
and monitoring on the spot.
By checking trainer protocols of sessions, adherence to
intervention protocols will be improved by giving feed-
back to the trainers. In addition, all sessions in both the
IG and CG will be recorded by audiotapes. Analysis with
respect to protocol violations will be conducted by a
trained person blind to treatment allocation.
Hypotheses
Our primary hypothesis postulates that children in the
IG will experience a more pronounced and sustained re-
duction of the frequency and intensity of abdominal pain
than children in the CG.
Secondary hypotheses postulate that after treatment,
children in the intervention group - compared to an active
control group - will experience (i) higher improvement in
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increase in the use of adequate pain-related coping and
cognitions, and (iii) a more pronounced improvement in
self-efficacy.
Additionally, we assume that children and parents
with more pronounced psychosocial strain gain less
from treatment than those experiencing low strain.Outcome variables
Primary outcome measure
The primary outcome is the course of pain frequency
and intensity of FAP (composite score) from pretreat-
ment (T1) to post-treatment (T2), 3-month (T3) and 12-
month follow-up (T4). Pain symptoms will be assessed
via self-report using the pain diary, which has already
successfully been implemented in prior trials [20-22].
On 14 consecutive days, children should report intensity
of pain on a 10-point visual analog scale. Pain duration
and frequency are derived from reports on time spans of
when the pain arose.Secondary outcome measure
Psychosocial well-being (health-related quality of life)
and pain coping, cognitions and self-efficacy are of clin-
ical relevance and represent the secondary outcomes. All
secondary outcomes are assessed by validated question-
naires as self or proxy reports.Heath-related quality of life
Health-related quality of life (HRQoL) is assessed by the
German version of the Pediatric Quality of Life Inven-
tory. (PedsQL; [35]). This 23-item questionnaire covers
four dimensions of HRQoL (physical, emotional, school,
and social). This measure showed sufficient to good in-
ternal consistency in previous studies (α = .68 to α = .80;
[20,21]). In addition, we assess the child’s pain-related
quality of life by the illness module of KINDLR [36],
which covers six items. Children are to rate the degree
of difficulties for each item on a five-point scale (never
to almost always). HRQoL will be assessed in both the
child and parent report.Pain - related coping and cognitions
Pain-related coping will be assessed by the German ver-
sion of the Pediatric Pain Coping Inventory (PPCI-
revised; [37,38]). The questionnaire includes three
subscales of behavior-related coping strategies when the
child is in pain: passive pain coping (for example, ‘I go to
bed’ (10 items, α = .68)), seek for social support (for ex-
ample, ‘I have my mother, father or a friend sit with me’
(8 items, α = .80)) and positive self-instruction (for ex-
ample, ‘I tell myself to be brave’ (7 items, α = .63)).Self-efficacy
For assessing child’s pain-related self-efficacy, we use the
self-efficacy scale by Bursch [39]. Children are asked to
rate how sure they are to pursue everyday activities
when they are in pain (for example, ‘make it through a
school day’ or ‘be with your friends’) on a five-point
scale (very sure to very unsure). This seven-item meas-
ure showed good internal consistency in the validation
study (α = .80; [39]).
Predictors
In addition to the confirmatory aspects of this trial, fur-
ther child- and parent-related variables will be assessed
for analyzing predictive or moderating influences on treat-
ment effects. Child and parental strain will be analyzed
with respect to their impact on treatment outcome.
Further, the amount of healthcare utilization and
school attendance will be assessed at baseline and during
follow-up.
Points of measurement
Applying an observer-blind design, data are collected by
questionnaires for children and parents at four points of
measurement. Pre-intervention (T1) and postinterven-
tion (T2) will take place at the study centers. As the pri-
mary outcome is assessed by a pain diary over 14 days,
T1 and T2 are located 14 to 21 days before and after the
intervention phase. Follow-up assessment will take place
3 (T3) and 12 (T4) months after intervention, also
including pain diaries and questionnaires for child and
parents. Follow-up data will be collected via mail by the
University of Potsdam.
The issue of concomitant care and use of other med-
ical or psychological services is included in patient infor-
mation prior to study inclusion. The families are not to
utilize other therapeutic approaches for FAP such as
pain medication or other treatments. Due to ethical rea-
sons, medical or psychological consultations are not pro-
hibited during the follow-up time span. Data on the
consultation rate are included in the follow-up survey.
Sample size - power analysis
The calculations rely on the high effect size of our pri-
mary outcome (d = 1.09 for the composite pain score;
see [21,22]) and correlation among repeated measures
0.8 (see [20-22]). Since our recent single-site study
included a 3-month follow-up and a waiting list control
group (instead of an active control group [21,22]), power
analysis for the primary outcome is based conservatively
on a medium effect size (f = 0.25; d = 0.6). Independent
variables are intervention (2), gender (2), age (2) and site
of intervention (5), forming a total of 23*5 = 40 groups.
In the study centers, n = 450 children will be assessed
for eligibility and a total number of n = 112 children will
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assume a drop-out rate of 20% [cf. 18], resulting n = 112
children to be analyzed in the intention-to-treat analysis
(ITT) and n = 90 children for the per protocol analysis
(PPA).
Drop-out rate
In our pilot study we did not observe drop-out of pa-
tients. In 9 out of 10 intervention studies, drop-out rates
are below 25% [18]. We assume a loss of 20% due to
drop-outs during the follow-up time span (cf. [40]). To
prevent selective drop-out and incomplete outcome
data, all participants will be reimbursed for completely
filling in the questionnaires and the pain diary in the
follow-up period.
Randomization
Allocation sequences are generated centrally at the
Institute of Epidemiology at University Clinic of
Hamburg-Eppendorf (KW). It will be mutually ran-
domized in IG and CG with a 1:1 ratio. Each patient’s
position on allocation sequence is defined by computer-
generated random-numbers and the date of informed
consent (chronologically sorted).
As groups are assigned parallel and the interventions
are to be carried out mutually, blocking is dependent on
the group sizes. Block sizes range between 6 and 16 pa-
tients. The total number of each block is dependent on
the total number of groups to be trained. As in this trial,
a maximum of 25 groups are to be trained; the number
of blocks of 6 and 8 patients is restricted to five each.
The randomization procedure, in order to prevent
selection bias, occurs centrally at the University of
Potsdam by a person not involved in the intervention
process and data analysis. We realize a stratified (accord-
ing to center) block randomization. Randomization and
allocation to interventions occur after assessment of
pre-data and before the interventions start. Results of
randomization will be provided directly only to the
trainers via email (allocation concealment). Each center
has to realize four different groups; at the first block of
interventions, the trainer may choose the trial arm (IG
versus CG); in the second block, the trainers have to
change the trial arm.
The effectiveness of the randomization is evaluated
post-hoc by descriptive statistical comparisons between
IG and CG in known and presumed baseline predictors
of treatment success (for example, pain history of the
parents and socio-economic status) and relevant socio-
demographic data (age and sex).
Blinding
The medical and psychological assessments are blinded
as these precede randomization. After assignment tointerventions, the outcome assessors (study nurse and
site investigators) and principle investigator will be
blinded. While patients and parents will be blinded, blind-
ing of trainers in the treatment is not possible. However,
trainers are not involved in the assessment process.
Group allocation will be coded by different letters;
only the trainers and the administrator of randomization
results will be informed about the corresponding
intervention.
The primary outcome will be reported by the children
themselves, who are not aware of their respective treat-
ment allocation. Assessment of data is blinded on all
points of measurement. Follow-up data will be assessed
by telephone interviews (blinded interviewer) with the
younger children and questionnaires for older children
and the parents. Information material and question-
naires in the follow-up phase will be sent out directly to
the participating families. Data collection and data ana-
lysis are independent. Data entry is operated by com-
puter scanning and is therefore blinded.
Early unblinding is not intended. Regular unblinding
occurs after complete data collection, that is, after the
last data of T4 is collected and entered into data set.
Process data of the intervention-specific pain diaries will
be added to the data set after all other data are entered
and therefore constitutes the first step of unblinding.Stopping rules
For the individual patient, it is stated that children can
discontinue treatment in case of observed unusual, con-
tinued and increased, severe bodily complaints or in case
of red flags. Then, the study physician will be consulted,
and diagnostics and treatment are advised. The whole
intervention will be stopped in case of occurrence of se-
vere adverse effects in association with the intervention
in more than 5% of the children. A study center will be
closed when it fails to meet or adhere to the study
protocol in more than three cases in a row, or if for two
consecutive time spans, fewer than three children could
be included in the study over the course of 3 months.Ethical approval
This trial was approved by the Ethics Committee of
the University of Potsdam and the responsible ethics
committees/state chambers of physicians of the five
study centers. A list of ethical bodies can be found in
Additional file 1.
All study staff commit themselves to the Declaration
of Helsinki (Version 2013), as well as to all pertinent
national laws and the ICH guidelines for GCP issued
in June 1996 and CPMP/ICH/ 135/95 from July, 2002.
Important protocol modifications will be reported to all
relevant parties.
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Staff working in this trial will be bound by the duty of
confidentiality. The respondents’ privacy and anonymity
is safe-guarded as personal patient data will be stored in
a restricted room separately from the questionnaires.
The latter are coded in an anonymous way before their
transfer to the central study office where data entry and
analysis will take place. All personalized data (addresses)
are destroyed after the termination of follow-up. The
participating treatment facilities will only receive aggre-
gated statistical data as feedback. All potential study par-
ticipants receive adequate written information about the
aims and implications of the study before consent is
given. Informed consent will be obtained from children
and their parents by the site investigators.
Data analytic plan
Missing values will be replaced by unbiased substitution
(EM-algorithm). Data will be analyzed by intention to
treat (ITT) supplemented by a per protocol analysis
(PPA) to test for effects of treatment adherence.
Primary analysis of the primary endpoints
An analysis of covariance will be performed in the ITT
population, comparing the log area under the pain inten-
sity curve from intervention to 12-month follow-up be-
tween the two random groups adjusted for the baseline
measurements. Length of pain episodes will be analyzed
analogously. Frequencies will be analyzed using a Pois-
son regression model.
Confirmatory analysis
In terms of clinical relevance, the composite pain score
is the most prominent outcome: a substantial pain re-
duction is mandatory for treatment efficacy. We there-
fore apply a hierarchical testing procedure; the number
and length of pain episodes will be tested only if there is
a significant difference between the treatment groups in
the log area under the curve (auc) of pain intensity.
These endpoints will be tested to an alpha level of 2.5%;
therefore, under this hierarchical design the overall alpha
level of the trial will not exceed 5%.
Analysis of secondary outcomes
Further, we will analyze primary and secondary outcome
measures using a mixed model, adjusting for the therap-
ist (random effect) and baseline measures (including age,
gender, duration of illness, age at onset and the baseline
measure of the outcome of interest).
Exploratory analyses
We will also explore subscales of the outcome measures
to see if there are indicators of treatment effects within
these subscales.In further exploratory analyses, we will include other
baseline predictors in the model and explore their po-
tential effect modification; moreover the effect of time-
varying predictors will also be investigated. In a sensi-
tivity analysis, we will explore the effect of missing
values using various imputing methods (best and worst
observation carried forward, last observation carried for-
ward, full-information maximum likelihood and multiple
imputation).
Descriptive analysis
All available data will be analyzed descriptively for each
intervention group. Differences in baseline variables will
be analyzed by appropriate tests (for example, the Chi
squared test, Kruskal-Wallis test, or analyses of variance)
in pairwise comparisons between the two treatment
groups.
Monitoring and data management
We concentrate our quality assurance and monitoring
on two aspects: standardization of recruitment and data
collection, and standardization/fidelity of intervention.
Monitoring
Regular monitoring on the spot includes supervision of
study nurses, control of protocol adherence, adherence
to intervention protocol and data quality assurance.
In addition, for coordinating the trial across the study
centers, there will be, in addition to the above mentioned
monitoring on the spot, principle investigator (PI) and
site investigator conference calls for cross-site reliability,
standardization and monitoring by checking compliance
to the protocol, inclusion/exclusion criteria and progress
of the intervention (individually, every month and for all
trial sites and the coordinator, every 3 months). For assur-
ing the quality of treatment, the therapist and evaluator
will be in contact via conference calls as well.
Follow-up assessment is monitored by the principle in-
vestigator. Audits can be held by the funding organization
at any time and the process will be independent from the
sponsor and the investigators.
Data management
Database management, randomization and the biometri-
cal calculations will be carried out at the Department of
Medical Biometry and Epidemiology (KW) and University
of Potsdam (PW, CC). The study will be reported accord-
ing to the CONSORT criteria for non-pharmacological tri-
als [41] and will be supplemented according to the TIDieR
guidelines [42]. For all patients, the informed consent doc-
uments will be checked. Data entry will be conducted by
electronic scanning of questionnaires, which includes
double checking of data. Additionally, 20% of the data
will be double checked by staff. The primary outcome
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source data verification of the key data will be performed
in a random sample of 40.0% of the patients. Data man-
agement has the opportunity to conduct queries regarding
data quality and integrity.
Assessment of safety
Since we do not expect adverse effects of the psycho-
logical intervention, we decided to form a multidisciplin-
ary scientific advisory board (Trial Steering Committee,
TSC) to oversee and monitor the whole trial. The mem-
bers are experts in the field of chronic pain and will
supervise the trial to ensure data safety. The TSC will
receive recruitment and retention updates on a regular
basis. According to the nature of the study, those per-
sons monitor the progress of the study (for example,
achievement of milestones, percent of recruited patients
and adverse events) as well as adherence to the study
protocol. There will be two meetings between the inves-
tigator and the advisory board at enrollment start and at
last recruitment. The committee itself has the right to
actively address any study issues with the principle
investigator.
On all relevant stages of the trial, safety aspects are
considered and monitored by psychological and medical
screening and ongoing monitoring with regard to ad-
verse effects and adherence.
In general, we do not expect any severe adverse effects
of the interventional approach since the intervention
consists of well-established pain management strategies
(IG) or information delivery (CG). So far, neither adverse
side effects nor such negative experiences are reported
in previous studies implementing the respective inter-
ventions [20-22,43].
Adverse events (AEs), including chronic or recurrent
physical and psychiatric illness, as well as all reports and
results have to be documented in patient’s health records
and case report forms. Documentation of AEs includes
the type of AE, starting and ending point, severity, caus-
ality to intervention, intensity and result.
Adverse events may be reported by site investigator,
study nurse and trainer during the course of the inter-
ventions and will be assessed in follow-up measurements
from the first training session of the children. The ethics
committee at the site, the principle investigator and the
TSC will be informed immediately.
Discussion
FAP represents a considerable strain on children and their
families and causes increased healthcare utilization. In our
previous study, children suffered for more than two years
from FAP [19]. Current evidence suggests that psycho-
logical treatments can lead to a clinically significant reduc-
tion of pain and, almost certainly, of psychological straintoo [13-18]. As increased health care utilization, especially
the repeated diagnostic procedures, causes high health
care costs ($6104.30 US per child; [5]) appropriate man-
agement of FAP is urgently needed and will reduce these
costs substantially. Thus demonstrating efficacy and feasi-
bility in a multicenter study, psychological treatments for
FAP will be available for affected children and their fam-
ilies and could be easily implemented in clinical practice.
Furthermore, psychological support is not part of the
standard medical care for patients with FAP in Germany;
therefore, participation in this multicenter study may im-
prove the quality of patient care. Furthermore, the group
setting offers an economically and emotionally advanta-
geous approach.
Generalizability
Participants are recruited from five pediatric gastroenter-
ology outpatient clinics throughout Germany using con-
secutive and active recruitment strategies. This broad
strategy and the specified sample characteristics with re-
spect to age, gender and psychological strain allow recruit-
ing of a representative sample of FAP patients. This will
enhance external validity and enable generalization of the
results.
Dissemination
Beyond regular publication, the results of the trial will be
used for dissemination of the intervention as well as for
the establishment of international collaboration with re-
lated study groups to further disseminate the evidence-
based treatment program and improvement of care for
children with FAP. Collaborations with self-help organiza-
tions will enhance the dissemination of the results and the
implementation of the treatment approach in clinical
practice as well.
Strengths of the trial
This trial will add to our current knowledge in several
ways. First, the inclusion of an active control group in-
stead of a waiting list control group is able to ensure
that effects are due to treatment content, rather than to
nonspecific patient-therapist factors [16]. Second, a 3-
and 12-month follow-up will enhance our knowledge on
the maintenance of treatment effects. Third, the imple-
mentation of the program in several centers will increase
the generalizability of treatment effects. Fourth, includ-
ing a broad range of psychosocial variables for children
as well as their parents allows the detailed analysis of
psychosocial treatment effects as well as the analysis of
predictors and mediators.
Trial status
The trial is currently recruiting.
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